Ocular Therapeut SEC Filings

Ocular Therapeutix, Inc. (OCUL) reported an insider transaction by its Chief Strategy Officer on a Form 4. On 11/24/2025, the officer sold 1,878 shares of common stock in a transaction coded “S,” at a weighted average price of $12.04 per share.

According to the footnotes, the sale was executed under a durable automatic sale instruction adopted on February 21, 2024, to cover tax withholding obligations tied to the vesting of restricted stock units on November 22, 2025, and is described as non-discretionary. After this sale, the officer beneficially owned 277,860 shares of Ocular Therapeutix common stock in direct form.

Ocular Therapeutix (OCUL) Executive Chairman, President and CEO Pravin Dugel reported insider transactions on Form 4. On November 24, 2025, he sold 19,530 shares of common stock at a weighted average price of $12.04 per share under a durable automatic sale instruction adopted on February 21, 2024, to cover tax withholding from restricted stock units vesting on November 22, 2025. These sales were not a discretionary trade.

After this sale, he directly owned 3,157,960 shares. On November 26, 2025, his spouse transferred 49,754 shares for no consideration to the Pravin Dugel 2024 Irrevocable Trust, and the same number of shares was recorded as acquired by the trust. Following this transfer, 300,115 shares were held indirectly through the trust, and the reporting person remained the beneficial owner of those securities.

Ocular Therapeutix, Inc. insider filing: Chief Development Officer Peter Kaiser reported selling 3,007 shares of Ocular Therapeutix common stock on 11/24/2025 at a weighted average price of $12.02 per share. The filing states these shares were sold under a durable automatic sale instruction adopted on April 9, 2024 to cover tax withholding obligations tied to restricted stock units that vested on November 22, 2025, and that the sales do not represent a discretionary trade by the reporting person.

After this transaction, Kaiser beneficially owns 191,433 shares of Ocular Therapeutix common stock, held directly. The filing notes that the 3,007 shares were sold in multiple trades at prices ranging from $11.74 to $12.28, and that detailed trade information is available on request.

Ocular Therapeutix, Inc. (OCUL) reported an insider transaction by its Chief Scientific Officer, Jeffrey S. Heier. On 11/24/2025, he sold 3,469 shares of common stock at a weighted average price of $12.04 per share, through multiple trades between $11.80 and $12.3207. The filing states this was an automatic sale under a durable instruction adopted on April 9, 2024, to cover tax withholding obligations related to restricted stock units that vested on November 22, 2025, and that the trades were not discretionary. Following this transaction, Heier beneficially owned 245,940 shares of Ocular Therapeutix common stock in direct ownership.

Ocular Therapeutix (OCUL) Form 4: Chief Business Officer Namrata Saroj reported a sale of 25,865 shares of common stock on 11/05/2025. The transaction was executed to satisfy tax withholding obligations tied to restricted stock units that vested on 11/04/2025, under a durable automatic sale instruction adopted on 02/04/2025. The weighted average sale price was $10.74, with trades ranging from $10.5875 to $10.8704. Following the sale, she beneficially owns 174,135 shares, held directly.

Ocular Therapeutix (OCUL) reported Q3 results marked by heavier R&D spending as it advances AXPAXLI in Phase 3. Revenue was $14.5M versus $15.4M a year ago, while net loss widened to $69.4M from $36.5M. R&D rose to $52.4M (from $37.1M), reflecting increased clinical activity. Year to date, revenue was $38.7M and net loss was $201.3M.

The balance sheet showed cash and cash equivalents $344.8M as of September 30, 2025, plus approximately $445.4M in net proceeds from an underwritten common stock offering that closed on October 1, 2025. The company believes these resources will fund planned expenses and debt service for at least 12 months while observing a $20.0M minimum liquidity covenant under its Barings credit facility.

Q3 operating lines included product revenue of $14.5M, cost of product revenue of $1.8M, selling and marketing of $13.1M, and G&A of $16.0M. Shares outstanding were 213,047,472 as of October 31, 2025; 174,949,558 were outstanding at September 30, 2025.

Todd Anderman, Chief Legal Officer of Ocular Therapeutix, Inc. (OCUL), reported a non-discretionary sale of 11,132 shares of common stock on 10/08/2025 under a durable automatic sale instruction tied to a sell-to-cover election for the vesting of restricted stock units. The weighted-average price reported was $12.34, with individual sale prices ranging from $12.00 to $12.5114. Following the transaction, the reporting person beneficially owned 87,568 shares.

The sale was executed to satisfy tax withholding obligations and was not a discretionary trade by the reporting person. The reporting person adopted the automatic plan on 10/07/2024 and offered to provide detailed per-price sale information to the company or SEC staff upon request.

Ocular Therapeutix, Inc. filed a Form 144 reporting a proposed sale of 11,132 common shares valued at $137,400.05, with an approximate sale date of 10/08/2025 on NASDAQ. The shares were acquired on 10/07/2025 through restricted stock vesting under a registered plan, and payment (if any) was recorded as Not Applicable. The filing lists 173,995,221 shares outstanding for the issuer. No sales by the reporting person in the prior three months are reported. The filer affirms they are not aware of undisclosed material adverse information and includes broker details for Morgan Stanley Smith Barney LLC.